

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/131579 A1

(51) International Patent Classification:

A61K 31/502 (2006.01) *A61K 31/53* (2006.01)
A61K 31/573 (2006.01) *A61K 45/06* (2006.01)
A61K 31/58 (2006.01) *A61P 21/00* (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

(21) International Application Number:

PCT/EP2023/000002

(22) International Filing Date:

05 January 2023 (05.01.2023)

Published:

- *with international search report (Art. 21(3))*

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22000008.7 07 January 2022 (07.01.2022) EP

(71) Applicant: **METRIOPHARM AG** [CH/CH]; Europaallee
41, 8021 Zürich (CH).

(72) Inventors: **BRYSCH, Wolfgang**; Rabenhorststr. 7, 13505
Berlin (DE). **BREMBECK, Felix**; Kurfürstenstr. 126 A,
10785 Berlin (DE). **SCHUMANN, Sara**; Hauptstr. 1,
14554 Seddiner See (DE). **VON WEGENER, Jörg**; Ruh-
lebener Strasse 20, 13597 Berlin (DE).

(74) Agent: **METRIOPHARM DEUTSCHLAND GMBH**;
Am Borsigturm 100, 13507 Berlin (DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF CONGENITAL MUSCU-
LAR DYSTROPHIES

(57) Abstract: The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of congenital muscular dystrophies, especially Duchenne muscular dystrophy or Becker muscular dystrophy. The invention relates in particular to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes. Also a pharmaceutical combination of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts and a glucocorticoid for use in these indications is disclosed. Pharmaceutical compositions, advantageous formulation techniques and a method of treatment are disclosed.



WO 2023/131579 A1